Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-Claudin 18.2 antibody-drug conjugate JS107

An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC JS107 specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CLDN18.2-expressing tumor cells. In addition, JS107 kills tumor cells via antibody-dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC JS107
anti-Claudin 18.2 ADC JS107
anti-Claudin 18.2/MMAE antibody-drug conjugate JS107
anti-Claudin18.2 ADC JS107
anti-CLDN18.2 ADC JS107
Code name:JS 107
JS-107
JS107
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search